|
Gene: CXorf36 |
Gene summary for CXORF36 |
Gene summary. |
Gene information | Species | Human | Gene symbol | CXorf36 | Gene ID | 79742 |
Gene name | divergent protein kinase domain 2B | |
Gene Alias | 4930578C19Rik | |
Cytomap | Xp11.3 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9H7Y0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79742 | CXorf36 | HCC1 | Human | Liver | HCC | 7.74e-10 | 2.44e+00 | 0.5336 |
79742 | CXorf36 | HCC2 | Human | Liver | HCC | 1.33e-09 | 8.17e-01 | 0.5341 |
79742 | CXorf36 | HCC5 | Human | Liver | HCC | 4.31e-05 | 7.55e-01 | 0.4932 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CXorf36 | SNV | Missense_Mutation | c.875T>C | p.Ile292Thr | p.I292T | Q9H7Y0 | protein_coding | deleterious(0.04) | benign(0.124) | TCGA-A8-A07I-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
CXorf36 | SNV | Missense_Mutation | rs749712350 | c.844G>A | p.Asp282Asn | p.D282N | Q9H7Y0 | protein_coding | deleterious(0.02) | probably_damaging(0.966) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CXorf36 | SNV | Missense_Mutation | c.1166N>A | p.Cys389Tyr | p.C389Y | Q9H7Y0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E2-A1L9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
CXorf36 | SNV | Missense_Mutation | c.728G>A | p.Arg243Lys | p.R243K | Q9H7Y0 | protein_coding | deleterious(0.01) | possibly_damaging(0.789) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
CXorf36 | SNV | Missense_Mutation | c.310N>A | p.Asp104Asn | p.D104N | Q9H7Y0 | protein_coding | tolerated(0.07) | probably_damaging(0.922) | TCGA-MU-A51Y-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
CXorf36 | SNV | Missense_Mutation | rs775096087 | c.475N>T | p.Arg159Cys | p.R159C | Q9H7Y0 | protein_coding | deleterious(0.01) | probably_damaging(0.973) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
CXorf36 | SNV | Missense_Mutation | novel | c.1051N>C | p.Ser351Arg | p.S351R | Q9H7Y0 | protein_coding | tolerated(0.27) | benign(0.052) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CXorf36 | SNV | Missense_Mutation | novel | c.369N>T | p.Glu123Asp | p.E123D | Q9H7Y0 | protein_coding | tolerated(0.36) | benign(0.009) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CXorf36 | SNV | Missense_Mutation | novel | c.997G>T | p.Asp333Tyr | p.D333Y | Q9H7Y0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CXorf36 | SNV | Missense_Mutation | novel | c.768C>A | p.Phe256Leu | p.F256L | Q9H7Y0 | protein_coding | tolerated(0.17) | benign(0.015) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |